Objective To observe the efficacy of chemotherapy and chemo-endocrine therapy for patients with advanced gastric carcinoma featuring postoperative recurrence and metastasis in the near future. Methods From 54 cases of patients with advanced gastric carcinoma (all with pathological confirmation and objective indication) were randomized into two EAP (etoposide+ adriamycin + cis-platinum) and EAP-TAM (tamoxifen) groups for respective treatment. The estrogen receptor condition was also evaluated. Results The EAP-TAM effective rate of the ER positive group reached 73.3% and the EAP recovery rate was 50.0%. There was a statistical difference between the two groups significantly (P<0.05). The effective rates of EAP-TAM and EAP of the negative receptor groups were 50.0% and 52.9% respectively with no significant difference between them (P>0.05). The curative effect of EAP + TAM of the ER (+) patients was strengthened with the increase of the receptor content (P<0.05). No apparent TAM toxicity and side effect were observed. Conclusion For the ER positive gastric carcinoma, the endocrine therapy was effective, whereas ineffective for the ER negative gastric carcinoma.%目的观察化疗和化学-内分泌治疗对术后复发或转移的进展期胃癌患者的临床疗效.方法将54例进展期胃癌患者(均有病理证实和客观体征)随机分为EAP(足叶乙甙十阿霉素+顺铂)和EAP-TAM(三苯氧胺)两组进行治疗,同时测定雌激素受体的状态.结果对雌激素受体阳性患者EAP-TAM治疗组有效率为73.3%,而EAP治疗组仅为50.0%,两组之间有明显的统计学差异(P<0.05);对雌激素受体阴性患者,两组有效率分别为50.0%和52.9%,无统计学差异(P>0.05).在雌激素受体阳性患者中,EAP-TAM治疗的有效率与雌激素受体的含量呈正比关系.本组试验中没有观察到三苯氧胺的毒副作用.结论内分泌治疗对雌激素受体阳性的胃癌患者有着明显的疗效,而对雌激素受体阴性的胃癌患者无效.
展开▼
